Caitlin Brooks, NP
Psychiatric/Mental Health · Cheektowaga, NYNPI 1659701050
Payments from drug & device makers
Across 177 payments — averaging $43.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$3K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$887
- Alkermes, Inc.$703
- AbbVie$405
- Teva Pharmaceuticals USA, Inc.$382
- plus $927 from 9 others
What the payments were for
- Speaking & faculty fees$2,96339%
- Travel & lodging$1182%
- Food & beverage$4,37357%
- Education$2093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 13 | $3,168 |
| Neurocrine Biosciences, Inc. | 28 | $1,191 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $887 |
| Alkermes, Inc. | 20 | $703 |
| AbbVie | 27 | $405 |
| Teva Pharmaceuticals USA, Inc. | 18 | $382 |
| Otsuka America Pharmaceutical, Inc. | 22 | $376 |
| Johnson & Johnson | 7 | $234 |
| Gilead | 1 | $90 |
| Lundbeck LLC | 4 | $74 |
| Axsome Therapeutics, Inc. | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERSERIS$2,963
- INGREZZA$745
- ARISTADA$480
- CAPLYTA$376
- ARISTADA INITIO$120
How this compares
$7,663 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 49 | $162,209 |
| IngrezzaValbenazine Tosylate | 19 | $159,524 |
| Abilify MaintenaAripiprazole | 56 | $155,024 |
| Invega TrinzaPaliperidone Palmitate | 11 | $80,523 |
| CaplytaLumateperone Tosylate | 16 | $23,260 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,469 |
| TrintellixVortioxetine Hydrobromide | 24 | $13,560 |
| Lurasidone Hcl | 40 | $5,407 |
| BelsomraSuvorexant | 11 | $4,691 |
| Atomoxetine Hcl | 24 | $2,778 |
| Aripiprazole | 96 | $1,581 |
| Buspirone Hcl | 94 | $1,337 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $1,323 |
| Clonazepam | 104 | $1,312 |
| Fluvoxamine Maleate | 19 | $1,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $703 | $162,20949 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,191 | $159,52419 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $376 | $155,02456 claims |
| Johnson & JohnsonInvega Trinza | $234 | $80,52311 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $887 | $23,26016 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $29 | $21,46912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $13,56024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Cheektowaga
- Leah MolinaCheektowaga$12K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.